天美传媒

Abstract

The potential benefits of using passively administered antibodies for immunization against infectious diseases, for targeting tumors, and for identifying injured tissue are well accepted. However, the heterogeneity of the immune response as well as the technical and possible ethical problems involved in generating human antibodies has prevented the full use of the natural products of the human humoral immune system. The hybridoma technology developed by Kohler and Milstein promised to solve these problems. This technology makes it possible to immortalize the antibody-forming cells from an immunized host by fusion with a myeloma cell and to generate clones of cells that will produce a single, homogeneous antibody. The hybridoma cells can be frozen, grown in mass culture, or injected into an animal to form tumors which produce large amounts of the antibody. The ability to freeze the cells for long-term storage makes it possible to have the same antibody available indefinitely. This is crucial for carrying out clinical trials. The hybridoma technology has made it possible for the first time to generate mono specific antibodies to antigens which are impure and often poorly characterized. The bio-availability libraries of mono clonal antibodies allows selection of antibodies with specific affinities and functional characteristics.

Biography

M. Hima Bindu is pursuing M.Pharmacy (Analysis) from School of Pharmacy, Anurag Group of Institutions, JNTU-H. She completed her graduation from Sri Indu Institute of Pharmacy, JNTU-H. She has presented a poster on Fourier Transform Infra Red Spectroscopy in a National level seminar competition.